Final analysis of phase 3 CheckMate 214 (1096 patients, advanced renal cell carcinoma, median follow-up 9.3 years): nivolumab plus ipilimumab vs sunitinib improved OS in intermediate/poor-risk patients (HR 0.69; 108-month OS 30.2% vs 18.7%), with fewer grade 3-4 adverse events.
RCTn = 1,096 patients
Choueiri et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial